eShowcase: LabPas CT 2.5
Phase I package adds formulary accountability, recruitment, lab, and EDC features
Phase I package adds formulary accountability, recruitment, lab, and EDC features
LabPas CT 2.5
Green Mountain Logic (Montpellier, VT) has added formulary accountability, recruitment, clinical lab, and EDC components to LabPas CT, its software package designed for Phase I management. LabPas CT 2.5 deploys PDAs on clinic floors for scanning patient and collection vessel barcodes and RFIDs to eliminate error potential. It provides real-time electronic data entry for collection times, comments, dosing, vital signs, and adverse events, and can adapt to changing protocols.
Enhancements in the latest version of LabPas CT allow users to track and manage the entire fomulary chain including accountability, distribution, reconciliation, returns, and destruction. The package also allows users to manage subject information such as biometrics, and handles scheduling and study assignment tasks. Also, the new clinical lab component of LabPas CT integrates clinical trial results into the study database, and the software exports clinical study data in a variety of formats for easy eCRF creation.
Green Mountain Logic, (866) LABPAS1, www.labpas.com
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Study Finds Many Randomized Clinical Trials Have Poorly Justified Exclusion Criteria
January 21st 2025Investigators find that most exclusion criteria in critical care randomized clinical trials are justifiable, but 60% include at least one poorly justified exclusion, most commonly affecting pregnant or lactating individuals.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
